Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

10617 Background: Whether trastuzumab should be continued after tumor progression remains unknown.We describe the activity of successive trastuzumab-containing regimens in patients with HER2-overexpressing metastatic breast cancer, as well as the response rate, time to progression and predictive factors for response. METHODS Descriptive retrospective… (More)